Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy.
complete response
minimal residual disease
multiple myeloma
next gene sequencing
treatment strategy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
04
2022
accepted:
06
07
2022
entrez:
2
9
2022
pubmed:
3
9
2022
medline:
3
9
2022
Statut:
epublish
Résumé
Assessment of minimal residual disease (MRD) is becoming a standard diagnostic tool for curable hematological malignancies such as chronic and acute myeloid leukemia. Multiple myeloma (MM) remains an incurable disease, as a major portion of patients even in complete response eventually relapse, suggesting that residual disease remains. Over the past decade, the treatment landscape of MM has radically changed with the introduction of new effective drugs and the availability of immunotherapy, including targeted antibodies and adoptive cell therapy. Therefore, conventional serological and morphological techniques have become suboptimal for the evaluation of depth of response. Recently, the International Myeloma Working Group (IMWG) introduced the definition of MRD negativity as the absence of clonal Plasma cells (PC) with a minimum sensitivity of <10
Identifiants
pubmed: 36052251
doi: 10.3389/fonc.2022.932852
pmc: PMC9426755
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
932852Informations de copyright
Copyright © 2022 Ferla, Antonini, Perini, Farina, Masottini, Malato, Marktel, Lupo Stanghellini, Tresoldi, Ciceri and Marcatti.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Adv Ther. 2022 May;39(5):1976-1992
pubmed: 35246820
Blood Adv. 2018 Nov 13;2(21):2811-2813
pubmed: 30355580
Ann Oncol. 2022 Jan;33(1):117
pubmed: 34857439
Clin Chem. 2009 Aug;55(8):1510-6
pubmed: 19520760
Haematologica. 2014 Feb;99(2):360-4
pubmed: 24038024
Lancet. 2019 Jul 6;394(10192):29-38
pubmed: 31171419
J Mol Diagn. 2018 Nov;20(6):859-870
pubmed: 30165206
Biomark Res. 2021 Oct 14;9(1):75
pubmed: 34649622
Lancet Oncol. 2019 Jan;20(1):5-6
pubmed: 30559052
Blood. 2018 Dec 6;132(23):2456-2464
pubmed: 30249784
Haematologica. 2018 Dec;103(12):2088-2096
pubmed: 30237262
Leukemia. 2019 Aug;33(8):2022-2033
pubmed: 30992504
Blood Cancer J. 2021 Jun 3;11(6):106
pubmed: 34083504
Bone Marrow Transplant. 2016 Dec;51(12):1565-1568
pubmed: 27595280
J Clin Oncol. 2013 Jul 10;31(20):2540-7
pubmed: 23733781
Blood Cancer J. 2020 Mar 2;10(3):25
pubmed: 32123158
Blood Cancer J. 2017 Dec 5;7(12):639
pubmed: 29209089
J Clin Oncol. 2017 Sep 1;35(25):2911-2918
pubmed: 28686535
Clin Cancer Res. 2021 Oct 1;27(19):5195-5212
pubmed: 34321279
N Engl J Med. 2018 Feb 8;378(6):518-528
pubmed: 29231133
Leuk Lymphoma. 2018 Aug;59(8):1772-1784
pubmed: 29019452
Blood. 2014 May 15;123(20):3073-9
pubmed: 24646471
Haematologica. 2017 Jun;102(6):1105-1111
pubmed: 28183851
Best Pract Res Clin Haematol. 2020 Mar;33(1):101149
pubmed: 32139014
Immunol Rev. 2018 Jul;284(1):132-147
pubmed: 29944755
N Engl J Med. 2014 Sep 4;371(10):906-17
pubmed: 25184863
Leukemia. 2019 Jul;33(7):1713-1722
pubmed: 30573775
Leukemia. 2021 Jan;35(1):18-30
pubmed: 32778736
Leukemia. 2013 Jan;27(1):213-9
pubmed: 22955329
Front Oncol. 2020 May 27;10:860
pubmed: 32537439
PLoS One. 2019 Mar 22;14(3):e0211600
pubmed: 30901326
Ann Oncol. 2010 Feb;21(2):325-330
pubmed: 19633044
Front Oncol. 2020 Jan 31;10:1
pubmed: 32076595
J Clin Oncol. 2017 Sep 1;35(25):2900-2910
pubmed: 28498784
Leukemia. 2017 Oct;31(10):2094-2103
pubmed: 28104919
Leukemia. 2003 Dec;17(12):2257-317
pubmed: 14671650
Eur J Haematol. 2020 Mar;104(3):190-197
pubmed: 31763708
JAMA Oncol. 2015 Sep;1(6):746-54
pubmed: 26181891
Leukemia. 2003 Jun;17(6):1051-7
pubmed: 12764368
Bone Marrow Transplant. 2006 Jan;37(1):1-18
pubmed: 16258534
J Clin Oncol. 2017 Oct 10;35(29):3279-3289
pubmed: 28742454
JAMA Oncol. 2021 Jun 01;7(6):862-868
pubmed: 33856405
N Engl J Med. 2019 May 30;380(22):2104-2115
pubmed: 31141632
Int J Mol Sci. 2019 Jun 10;20(11):
pubmed: 31185671
Adv Exp Med Biol. 2018;1100:141-159
pubmed: 30411265
Leukemia. 2014 Jun;28(6):1299-307
pubmed: 24342950
Blood. 2022 Feb 10;139(6):835-844
pubmed: 34289038
Blood Adv. 2020 Dec 8;4(23):5988-5999
pubmed: 33284948
Blood. 2021 Jan 7;137(1):49-60
pubmed: 32693406
Nat Commun. 2017 Aug 16;8(1):268
pubmed: 28814763
Leukemia. 2018 Aug;32(8):1838-1841
pubmed: 29749395
PLoS One. 2020 Aug 31;15(8):e0237155
pubmed: 32866200
Leukemia. 2006 Sep;20(9):1467-73
pubmed: 16855634
Lancet Oncol. 2017 Apr;18(4):e206-e217
pubmed: 28368259
N Engl J Med. 2017 Apr 6;376(14):1311-1320
pubmed: 28379796
Front Oncol. 2019 Jun 06;9:449
pubmed: 31245284
Blood Cancer J. 2020 Oct 30;10(10):108
pubmed: 33127891
Front Oncol. 2022 Jan 26;11:801851
pubmed: 35155198
J Clin Oncol. 2013 Dec 20;31(36):4529-35
pubmed: 24248686
Clin Cancer Res. 2016 Nov 15;22(22):5428-5433
pubmed: 28151710
Ann Oncol. 2017 Oct 01;28(10):2503-2510
pubmed: 28945825
Clin Cancer Res. 2017 Aug 1;23(15):3980-3993
pubmed: 28428191
J Clin Oncol. 2020 Mar 10;38(8):784-792
pubmed: 31770060
Hematol Oncol. 2017 Sep;35(3):323-328
pubmed: 27140172
Ann Ist Super Sanita. 2021 Oct-Dec;57(4):300-313
pubmed: 35076420
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
Blood. 2009 Sep 24;114(13):2617-8
pubmed: 19641191
Lancet Oncol. 2021 Oct;22(10):1378-1390
pubmed: 34529931
Am J Hematol. 2022 May;97 Suppl 1:S3-S25
pubmed: 35234302
Exp Hematol. 2021 Jun;98:14-24
pubmed: 33823225